Pure Global
NCT00225667

Irbesartan for the Prevention of Atrial Arrhythmias and Cardiac Electrical Remodeling in Patients With Hypertension and Permanent Pacemakers

Irbesartan for the Prevention of Atrial Arrhythmias and Cardiac Electrical Remodeling in Patients With Hypertension, Permanent Pacemakers and Risk Factors for Developing Atrial Fibrillation
Connolly, Stuart, M.D.·Phase 3·ClinicalTrials.gov·drug
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Atrial Fibrillation,Hypertension
Drug/Device/Intervention
Irbesartan
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Connolly, Stuart, M.D.
Location
Hamilton, Canada
Timeline & enrollment
Phase
Phase 3
Start date
Dec 01, 2005
End date
Jul 01, 2007
Enrollment
200 participants
Primary outcome

Time to recurrent AHRE ( 220/min for 2 minutes)

Summary

The purpose of this study is to determine whether irbesartan will reduce the rate of
 recurrent atrial high rate episodes and the development of clinical sustained atrial
 fibrillation in patients with hypertension and permanent pacemaker.

ICD-10 classifications
Chronic atrial fibrillationPersistent atrial fibrillationParoxysmal atrial fibrillationAtrial fibrillation and flutterAtrial fibrillation and atrial flutter, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT00225667
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT00225667 through Pure Global AI's free database. This Phase 3 trial is sponsored by Connolly, Stuart, M.D. and is currently status unknown. The study focuses on Atrial Fibrillation,Hypertension. Target enrollment is 200 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.